BRAF and neoplasm: Additionally, we show that TERT amplification is able to prognosticate lower survival independently of other variables that also display predictive value such as age ≥ 55 years old, extrathyroidal extension, and BRAF mutations. In contrast to TERT amplification, the presence of BRAF mutations increases the likelihood of recurrence-free probability and decreases the risk of tumor-related death.